As a healthcare company committed to improving the lives of patients around the world, LivaNova is closely monitoring the coronavirus situation and is reacting accordingly as the issues evolve.
U.S. Temporary Modification to Product Indications for Use
To address coronavirus (COVID-19) and per the U.S. Food and Drug Administration, LivaNova is now permitted to modify cardiopulmonary products indications for use to include ECMO therapy beyond six hours. This applies to the following products:
We understand the additional challenges that COVID-19 has created for people with epilepsy and especially those with uncontrolled seizures. We encourage you to stay in contact with your healthcare team in order to make the best possible decisions both to optimize epilepsy care for you or your loved one and also to minimize the risks of COVID-19.